Dr. David Samadi and the Prostate Surgeries of the Future

Dr. David Samadi is one of the foremost surgeons of prostate cancer in the world. He is particularly enthusiastic about the uses of robotics in future surgeries. Samadi, who lives and works in New York, is the only surgeon who has performed a surgery using the SMART surgery technique via the da vinci robotic system. Samadi has said that the da vinci system is by far the most advanced tool for minimally invasive surgery. The current state of prostate surgery technology of any kind is a huge step up from the past traditional surgeries which required a large incision, usually resulted in lots of adverse side effects, and required much recovery time.

The now minimal incisions of the surgery mean the healing process will be much faster. Samadi says the new recuperation process now only takes one to three weeks. In addition (and most importantly to many) the da vinci system ensures that the nerves that control both the sexual system and the bladder are left whole and unharmed. He is a coveted speaker who speaks much as a valued member of both the American Urologic Association and the American Medical Association. He is also frequently invited to appear on Fox News.

So frequent, in fact, that it now takes place on a weekly basis. As a result, he is now considered a celebrity doctor. He is a huge encourager of testing for patients. He is especially so about the PSA (prostate specific antigen) test. These kinds of tests are conclusive proof about whether or not a patient requires prostate surgery. In his own practice, on average he will perform about 15 prostate surgeries a week. Because of his clear expertise in the field, he has become a very popular doctor. He has also become one of the highest-paid surgeons in the country. Samadi currently serves as the Chairman of Urology at Lenox Hill.

Dr. Clay Siegall’s Ambitious Plans with Seattle Genetics in the Cancer Therapy

Dr. Clay Siegall, the co-founder, Chairman, and CEO of Seattle Genetics, is known for his ambitious plans in simplified and targeted treatment regimes, especially in cancer therapy. Seattle Genetics has a market value close to $10 billion and employs at least 900 employees with a deep focus on research and marketing with a futuristic vision. “We are growing as a multi-product, global, oncology firm,” declared Dr. Siegall. He further pointed out that the company has many drugs in the pipeline, and he wanted the firm as an innovator in the biotech industry. The flagship drug of the company, Adcetris is an excellent therapy solution for Hodgkin lymphoma approved by the FDA. The expectation created by Seattle Genetics in the industry is huge that its stock price has tripled in the last five years.

Interestingly, under the leadership of Dr. Siegall, the company is very focused on its research, and in 2016, it spent more than $376 million – a 64 percent up from 2014. The biotech firm is basing its research in antibody-drug conjugate (ADC), a target antigen method. These drugs attach to the cancer cells and create toxin inside those cells to kill them. It means that while killing the cancer cells, the therapies do not harm the normal cells. It is a highly effective therapy considering the current radiation therapy or chemotherapy where healthy cells also face the damage from the treatment. Dr. Siegall confirms that as many as 11 more drugs are in the pipeline, and he sees a greater potential for sales with those.

Apart from a dedicated researcher in oncology, Dr. Siegall is also a visionary entrepreneur and brilliant manager. He helped the firm to raise $675 million through private and public financing in 2001 to expand its research activities. It should also be noted that Dr. Siegall led the company to issue its initial public offering as well, in the same year. He holds more than 15 patents and published his papers in at least 70 publications.

Dr. Siegall started his career with the National Cancer Institute, part of National Institutes of Health, in 1988. In 1991, he joined the Bristol-Myers Squibb Pharmaceutical Research Institute as a scientist and worked until 1997. Dr. Siegall left the firm to found Seattle Genetics in the year 1998. He completed his graduation from the University of Maryland in Zoology and gained his Ph.D. from George Washington University in Genetics. Dr. Siegall serves on the director boards of Ultragenyx Pharmaceutical and Alder BioPharmaceuticals.